|Table of Contents|

Dosimetric study of multi-channel 3D mold guided anodynia intracavitary/interstitial combined with three-dimensional image-guided brachytherapy for refractory cervical cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 22
Page:
4344-4349
Research Field:
Publishing date:

Info

Title:
Dosimetric study of multi-channel 3D mold guided anodynia intracavitary/interstitial combined with three-dimensional image-guided brachytherapy for refractory cervical cancer
Author(s):
LI Fenghu1; 2; XIANG Mei1; LI Jiehui1; 2; HONG Wei1; 2; MEI Fan1; 2; HU Lili1; 2; DU Yanjun1; 2; XU Congfeng2; LIU Wen2
1.Department of Oncology,Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550004,China;2.Department of Gynecological Oncology,Affiliated Cancer Hospital of Guizhou Medical University,Guizhou Guiyang 550004,China.
Keywords:
refractory cervical cancer; anodynia intracavitary/interstitial; three-dimensional image-guided brachytherapy; dosimetry
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2024.22.021
Abstract:
Objective:To evaluate the dosimetry and safety of anodynia intracavitary/interstitial combined with three-dimensional image-guided brachytherapy for refractory cervical cancer.Methods:From March 2022 to June 2023,we collected 50 patients with poorly regressed and eccentric refractory cervical cancer after external pelvic radiotherapy.The treatment methods included painless multi-channel 3D mold guided intracavitary/interstitial brachytherapy （IC/ISBT） treatment group and intracavitary brachytherapy (ICBT) treatment group.Statistical description of categorical data was expressed by rate,the measurement data of two groups were compared by t test for comparison of two independent samples,P＜0.05 was a statistical difference.Results:The volume of gross target volume(GTV-Tres),the prescribed dose received by 90% of the target (D90),and the percentage of the target included in the entire target volume (V100) of the 100% prescribed dose and the volume,D100,D90,and V100 of high risk clinical target volume(HR-CTV) in the IC/ISBT group were significantly higher than those of ICBT group,with statistical significance (P＜0.05).There was no significant difference in the prescribed dose received by 100% of the target (D100) between the two groups (P＞0.05).Dose of 1 cm3 (D1 cm3) and 2 cm3 (D2 cm3) for bladder,rectum,sigmoid colon,and small intestine was similar between the two groups,with no significant difference (P＞0.05).In addition,the time of operation was longer,the times of CT scanning,the number of inserted needles and the amount of bleeding of the IC/ISBT group were more than those of the ICBT group (P＜0.05).However,through anesthesia techniques,there was no statistically significant difference in NRS scores between the two groups of patients (P＞0.05).Conclusion:Choosing personalized source device intracavitary/interstitial combined with three-dimensional image-guided brachytherapy technology was selected for different patients.The application of painless operation under general anesthesia can ensure the volume dosimetry coverage of tumor target without increasing the irradiation dose of surrounding organs,and improve the comfort and compliance of patients.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ BHATLA N,AOKI D,SHARMA DN,et al.Cancer of the cervix uteri:2021 update［J］.Int J Gynaecol Obstet,2021,155(Suppl 1):28-44.
［3］ FOKDAL L,STURDZA A,MAZERON R,et al.Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer:Analysis from the retroEMBRACE study［J］.Radiother Oncol,2016,120(3):434-440.
［4］ LICHTER K,ANAKWENZE AKINFENWA C,MACDUFFIE E,et al.Treatment of cervical cancer:overcoming challenges in access to brachytherapy［J］.Expert Rev Anticancer Ther,2022,22(4):353-359.
［5］ OTTER S,COATES A,FRANKLIN A,et al.Improving dose delivery by adding interstitial catheters to fixed geometry applicators in high-dose-rate brachytherapy for cervical cancer［J］.Brachytherapy,2018,17(3):580-586.
［6］ MENDEZ LC,WEISS Y,D' SOUZA D,et al.Three-dimensional-guided perineal-based interstitial brachytherapy in cervical cancer:A systematic review of technique,local control and toxicities［J］.Radiother Oncol,2017,123(2):312-318.
［7］ 张福泉.宫颈癌图像引导三维近距离后装治疗中国专家共识［J］.中华放射肿瘤学杂志,2020,29(9):712-717. ZHANG Fuquan.Chinese expert consensus on three-dimendional image guided brachytherapy for vervical cancer［J］.Chin Radiat Oncol,2020,29(9):712-717.
［8］ GRIGSBY PW,MASSAD LS,MUTCH DG,et al.FIGO 2018 staging criteria for cervical cancer:Impact on stage migration and survival［J］.Gynecol Oncol,2020,157(3):639-643.
［9］ CIBULA D,RASPOLLINI MR,PLANCHAMP F,et al.ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer-update 2023［J］.Int J Gynecol Cancer,2023,33(5):649-666.
［10］ VISWANATHAN AN,DIMOPOULOS J,KIRISITS C,et al.Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy:results of a prospective trial and preliminary guidelines for standardized contours［J］.Int J Radiat Oncol Biol Phys,2007,68(2):491-498.
［11］ The International Commission on Radiation Units and Measurements.Prescribing,recording,and reporting brachytherapy for cancer of the cervix［R］.New York:Oxford University Press,2013.
［12］ MAHANTSHETTY U,POETTER R,BERIWAL S,et al.IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer［J］.Radiother Oncol,2021,160:273-284.
［13］ SERBAN M,FOKDAL L,NIELSEN SK,et al.Characterization of combined intracavitary/interstitial brachytherapy including oblique needles in locally advanced cervix cancer［J］.Brachytherapy,2021,20(20):796-807.
［14］ QU HD,HAN DM,ZHANG N,et al.Intracavitary/interstitial applicator plus distal parametrial free needle interstitial brachytherapy in locally advanced cervical cancer:a dosimetric study［J］.Front Oncol,2020,10:621347.
［15］ 袁香坤,崔芒芒,苗珺珺,等.3D打印微创导向模板在术后复发性宫颈癌近距离治疗中的临床应用［J］.中国肿瘤临床,2018,45(24):1258-1262. YUAN XK,CUI MM,MIAO JJ,et al.Clinical application of 3D printed minimally invasive guided template in close up treatment of recurrent cervical cancer after surgery［J］.Chinese Journal of Clinical Oncology,2018,45(24):1258-1262.
［16］ GUTIERREZ MIGULEZ C,RODRIGUEZ VILLALBA S,VILLAFRANCA ITURRE E,et al.Recommendations of the Spanish brachytherapy group of the Spanish Society of Radiation Oncology and the Spanish Society of Medical Physics for interstitial high-dose-rate brachytherapy for gynaecologic malignancies［J］.Clin Transl Oncol,2023,25(4):912-932.
［17］ LOMBE D,CROOK J,BACHAND F,et al.The addition of interstitial needles to intracavitary applicators in the treatment of locally advanced cervical cancer:Why is this important and how to implement in low- and middle-income countries［J］.Brachytherapy,2020,19:316-322.
［18］ MURAKAMI N,OHNO T,TOITA T,et al.Japanese Society for Radiation Oncology Consensus Guidelines of combined intracavitary and interstitial brachytherapy for gynecological cancers［J］.J Radiat Res,2022,63(3):402-411.
［19］ JIANG P,QU A,WEI S,et al.The preliminary results of 3-dimensional printed individual template assisted 192Ir high-dose rate interstitial brachytherapy for central recurrent gynecologic cancer［J］.Technol Cancer Res Treat,2020,19:1-8.
［20］ POTTER R,TANDERUP K,SCHMID MP,et al.MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I):a multicentre prospective cohort study［J］.Lancet Oncol,2021,22(4):538-547.
［21］ MURAKAMI N,ANDO K,MURATA M,et al.An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma［J］.J Radiat Res,2022,63(3):412-427.
［22］ MURAKAMI N,WATANABE M,UNO T,et al.Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer［J］.J Gynecol Oncol,2023,34(3):e24.
［23］ JAHAN D,AHMAD S,THOMPSON S,et al.Dosimetric evaluation of the feasibility of utilizing a reduced number of interstitial needles in combined intracavitary and interstitial brachytherapy for cervical cancer［J］.J Appl Clin Med Phys,2023,24(2):e13833.
［24］ AMER SOC ANESTHESIOLOGISTSI,AMER LANE,SCHAUMBURG.Practice guidelines for moderate procedural sedation and analgesia 2018:A report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia,the American Association of Oral and Maxillofacial Surgeons,American College of Radiology,American Dental Association,American Society of Dentist Anesthesiologists,and Society of Interventional Radiology［J］.Anesthesiology,2018,128(3):437-479.
［25］ PETITT MS,ACKERMAN RS,HANNA MM,et al.Anesthetic and analgesic methods for gynecologic brachytherapy:A meta-analysis and systematic review［J］.Brachytherapy,2020,19(3):328-336.
［26］ SOMMAT K,LIN J,CHEW M,et al.Non-anesthetist-administered moderate sedation with midazolam and fentanyl for outpatient MRI-aided hybrid intracavitary and interstitial brachytherapy in cervix cancer:a single-institution experience［J］.J Contemp Brachytherapy,2021,13(3):286-293.

Memo

Memo:
贵州省抗癌协会科技计划项目［编号：抗协科计014（2023）］
Last Update: 1900-01-01